Fri, Apr 18, 2014, 5:07 AM EDT - U.S. Markets closed for Good Friday


% | $
Quotes you view appear here for quick access.

Vringo, Inc. Message Board

savage.j922 26 posts  |  Last Activity: Apr 11, 2014 9:46 AM Member since: Aug 28, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • savage.j922 by savage.j922 Apr 11, 2014 9:46 AM Flag

    Management is going to use this correction to repurchase shares. Just my opinion.

  • savage.j922 by savage.j922 Apr 7, 2014 7:31 AM Flag

    Soligenix Announces $200,000 NIDCR SBIR Grant Award Supporting Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer


    PR Newswire
    Soligenix, Inc.
    6 minutes ago




    PRINCETON, N.J., April 7, 2014 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Dental and Craniofacial Research (NIDCR) has awarded Soligenix a Small Business Innovation Research (SBIR) grant to support the conduct of its Phase 2, randomized, double-blind, placebo-controlled study evaluating SGX942, a first-in-class innate defense regulator, as a treatment for oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer.

    This Phase 2 study is a multicenter trial focused on patients with tumors of the mouth and oropharynx who often experience severe oral mucositis as a consequence of tumor treatment with intensity modulated radiation and chemotherapy. The primary efficacy will be assessed on the basis of the incidence and duration of both ulcerative and severe oral mucositis throughout the course of radiation treatment. Other key efficacy measures will assess patient reported outcomes, pharmacoeconomic parameters such as hospitalization and radiation-associated side effects including mouth stiffness (trismus) and dryness (xerostomia). Patient enrollment into the study commenced December 2013.

    "We are appreciative of the support provided by NIDCR for our Phase 2 clinical study of SGX942 in the treatment of oral mucositis," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. "Oral mucositis remains an extremely debilitating side effect of cancer treatments and is particularly severe and prevalent in head and neck cancer patients. We look forward to completing the study to demonstrate the potential clinical efficacy of SGX942."

    Dr. Schaber continued, "We remain aggressive in our pursuit of government grants and contracts across our entire pipeline as a way to secure non-dilutive funding to support multiple development programs, while effectively managing our cash position."

  • Article out this morning.

  • Reply to

    earnings out

    by tswenor7 Mar 26, 2014 8:01 AM
    savage.j922 savage.j922 Mar 26, 2014 8:46 AM Flag

    Its gonna be interesting to see how the market takes such a big loss. Might shake out some weak hands. I was hoping for some kind of update on the ongoing trials.

  • savage.j922 savage.j922 Mar 21, 2014 8:27 AM Flag

    they also bought back more stock, the outstanding share count is down to 469.6 million. I love this co!!!

  • Reply to

    SVA just filed Form SC 13D

    by cruise722 Mar 5, 2014 8:06 AM
    savage.j922 savage.j922 Mar 5, 2014 9:06 AM Flag

    Looks like Mr. Gregory (SJ strategic investments) likes to trade a small position. Still owns 2.1 million shares 3.8 %

  • savage.j922 by savage.j922 Mar 4, 2014 11:37 AM Flag

    Discover bought back another 1.1 million shares since last month. They are real close to retiring 10 percent of the outstanding stock in under 2 years. WOW!!!!

  • Reply to


    by heezdedjim_2002 Feb 27, 2014 8:36 AM
    savage.j922 savage.j922 Feb 27, 2014 9:06 AM Flag

    Is this something they will be able to sell to the private market, or will it all be scooped up by government orders? Private would be so much better from a pricing perspective!!!!

  • Baffles my mind that this is going on.....

  • savage.j922 by savage.j922 Feb 26, 2014 9:53 AM Flag

    I was happy adding @ 1.7, pickin up sum more

  • Reply to

    plug is being pulled

    by pechstein.carl Feb 21, 2014 4:33 PM
    savage.j922 savage.j922 Feb 22, 2014 4:20 PM Flag

    They are institutional investors, but really your gonna make a big deal out of someone selling 13,000 or 29,000 shares? Sounds more like pocket change for them. Doesn't sound like much conviction from them, as far as Tekla. They made money waited for a pullback and are back in, waiting for the next catalyst. When they will trade again for a profit.

  • Blue Calypso Receives Positive Notification From Patent Trial and Appeal Board (PTAB)

    Groupon's Petition Rejected by PTAB Regarding Four Key Claims


    Blue Calypso
    47 minutes ago



    DALLAS, Feb. 20, 2014 (GLOBE NEWSWIRE) -- Blue Calypso, Inc. (BCYP), a marketing analytics and brand advocacy innovator, has received notice that the Patent Trial and Appeal Board (PTAB) has decided not to institute a review of four claims of Blue Calypso patent number 8,438,055 ('055) despite Groupon's petition.

    "Now four claims in the '055 patent have been resolved in our favor," stated Blue Calypso CEO Bill Ogle. "Historically, the PTAB has shown a propensity to grant most petitions to review claims for Covered Business Method review (CBMR), but in this case was not convinced that these four claims should be reviewed."
    • In 2012 and 2013, Blue Calypso brought suit against Groupon, FourSquare, Yelp and IZEA, claiming infringement on five patents owned by Blue Calypso.
    • In June and August 2013, Groupon petitioned the PTAB for a review of all claims in the 5 issued patents owned by Blue Calypso.
    • In February 2014, the PTAB rejected Groupon's request to reexamine regarding four claims of the '055 patent.

    "We are pleased with the first PTAB action related to Blue Calypso and look forward to the results of the remaining CBMR proceedings later this year," concluded Ogle.

    About Blue Calypso, Inc.

    Blue Calypso, Inc. (BCYP) develops digital innovation products

  • savage.j922 by savage.j922 Feb 15, 2014 4:34 PM Flag

    I see all the negativity about Broadfin, but nothing mentioned about Tekla increasing to over 2 million shares. If I am reading the filing right, Broadfin has been selling for a while.

  • savage.j922 by savage.j922 Feb 14, 2014 11:32 AM Flag

    How is it, there is a P.R. for another grant.........and there is no volume to speak of? Some of my other positions have light volume, but this is ridiculous!!!!

  • savage.j922 by savage.j922 Feb 12, 2014 11:39 AM Flag

    Anticipation of news......will drive it up at the close. The unknown, will cause people to buy. I will try to listen in.......

  • savage.j922 savage.j922 Feb 5, 2014 6:44 AM Flag

    later in the same article they mention IPCI got their 3.1 million dollar payment, but it doesn't mention any thing about waiting for approval on the lower dosages.

  • Biotech News for Advancing Pharma Stocks: Company's Test Results Surpass Expectations For $3.5 Billion ADHD Market

    Text Size

    Published: Tuesday, 4 Feb 2014 | 9:05 AM ET






    CORAL SPRINGS, Florida, February 4, 2014 /PRNewswire/ --

    Market Briefing for leading pharma advancers along with clinical data reveals biotech company is on the verge of fulfilling glaring market need: Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS), Pfizer Inc. (NYSE: PFE), IntelliPharmaCeutics International Inc. (NASDAQ: IPCI), Alcobra Ltd. (NASDAQ: ADHD), Horizon Pharma, Inc. (NASDAQ: HZNP) and Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA)

    Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced positive clinical data for Eltoprazine in a Phase 2a clinical study Adult Attention Deficit Hyperactivity Disorder. The results from the study demonstrated statistically significant improvements of both doses of 5mg and 10mg vs. placebo in a range of ADHD clinical measures."Following a thorough statistical review of the data announced by Psychogenics in 2008 by an independent clinical CRO retained for due diligence purposes, an updated study report was submitted in the Investigator's Brochure in 2010 that was better than originally reported," said David A. Lowe, PhD member of the Amarantus Board of Directors. "There is a significant need for non-stimulant ADHD treatments in the marketplace, especially in light of recent regulatory oversight of abuse of currently approved treatments. We believe Eltoprazine may fill this market need." The ADHD market is valued at over $3.5 billion dollars, with approximately 35 million prescriptions written annually.

  • Reply to

    BlackRock owns 5.4 %

    by savage.j922 Jan 31, 2014 7:36 AM
    savage.j922 savage.j922 Jan 31, 2014 8:01 AM Flag

    I agree, this is just the start of the big boys coming in, anyone who has been here long enough isn't sweating any of this.......patience

  • savage.j922 by savage.j922 Jan 31, 2014 7:36 AM Flag


    Washington, D.C. 20549


    Under the Securities Exchange Act of 1934

    (Amendment No: )

    (Name of Issuer)

    Common Stock
    (Title of Class of Securities)

    (CUSIP Number)

    December 31, 2013
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to
    which this Schedule is filed:

    [X] Rule 13d-1(b)
    [ ] Rule 13d-1(c)
    [ ] Rule 13d-1(d)

    *The remainder of this cover page shall be filled out
    for a reporting person's initial filing on this form with
    respect to the subject class of securities, and for any
    subsequent amendment containing information which
    would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover
    page shall not be deemed to be "filed" for the purpose
    of Section 18 of the Securities Exchange Act of 1934
    ("Act") or otherwise subject to the liabilities of that
    section of the Act but shall be subject to all other
    provisions of the Act (however, see the Notes).

    CUSIP No. 92911N104

    (1)Names of reporting persons. BlackRock, Inc.

    (2) Check the appropriate box if a member of a group
    (a) [ ]
    (b) [X]

    (3) SEC use only

    (4) Citizenship or place of organization


    Number of shares beneficially owned by each reporting person with:

    (5) Sole voting power


    (6) Shared voting power


    (7) Sole dispositive power


    (8) Shared dispositive power


    (9) Aggregate amount beneficially owned by each reporting person


    (10) Check if the aggregate amount in Row (9) excludes certain shares

    (11) Percent of class represented by amount in Row 9


    (12) Type of reporting person


    Item 1.

    Item 1(a) Name of issuer:


    Item 1(b) Address of issuer's principal executive offices:

    New York NY 10017

    Item 2.

    2(a) Name of person filing:
    BlackRock, Inc.

    2(b) Address or principal business office or, if none, residence:
    BlackRock Inc.
    40 East 52nd Street
    New York, NY 10022

    2(c) Citizenship:
    See Item 4 of Cover Page

    2(d) Title of class of securities:

    Common Stock

    2(e) CUSIP No.:
    See Cover Page

    Item 3.

    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c),
    check whether the person filing is a:
    [ ] Broker or dealer registered under Section 15 of the Act;
    [ ] Bank as defined in Section 3(a)(6) of the Act;
    [ ] Insurance company as defined in Section 3(a)(19) of the Act;
    [ ] Investment company registered under Section 8 of the
    Investment Company Act of 1940;
    [ ] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
    [ ] An employee benefit plan or endowment fund in accordance with
    Rule 13d-1(b)(1)(ii)(F);
    [X] A parent holding company or control person in accordance with
    Rule 13d-1(b)(1)(ii)(G);
    [ ] A savings associations as defined in Section 3(b) of the Federal
    Deposit Insurance Act (12 U.S.C. 1813);
    [ ] A church plan that is excluded from the definition of an
    investment company under section 3(c)(14) of the Investment Company
    Act of 1940;
    [ ] A non-U.S. institution in accordance with
    Rule 240.13d-1(b)(1)(ii)(J);
    [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing
    as a non-U.S. institution in accordance with
    Rule 240.13d-1(b)(1)(ii)(J), please specify the type of

    Item 4. Ownership

    Provide the following information regarding the aggregate number
    and percentage of the class of securities of the issuer identified in Item 1.

    Amount beneficially owned:


    Percent of class


    Number of shares as to which such person has:

    Sole power to vote or to direct the vote


  • savage.j922 savage.j922 Jan 29, 2014 2:35 PM Flag

    don't forget MSFT will pay 5% of what google a limit. Is that limit 30, 40 ,50 million?

3.75-0.04(-1.06%)Apr 17 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.